There is increasing evidence that drug‐resistant tumor cells significantly depend on 90‐kDa ribosomal S6 kinase (RSK) activation; thus, RSK emerges as another essential component in the resistance process. This evidence concerns the gene RPS6KA1 and neoplasm.